Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Events / Business / Oncolytics Biotech appoints Glover,...
Business executive changes

Oncolytics Biotech appoints Glover, promotes McAdory

Analysis based on 7 articles · First reported Jun 02, 2026 · Last updated Jun 02, 2026

Sentiment
40
Attention
2
Articles
7
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The appointments of Steve-O>>> and John McAdory>>> are expected to strengthen Oncolytics Biotech>>>'s leadership and operational capabilities, potentially leading to increased investor confidence and a positive impact on its stock price. Steve-O>>>'s experience in strategic transactions, including the sale of GT Biopharma>>> to Johnson & Johnson>>>, suggests a focus on value creation for Oncolytics Biotech>>>.

biotechnology pharmaceuticals
Event Summary

Oncolytics Biotech>>> announced significant leadership changes, appointing Steve-O>>> to its Board of Directors and promoting John McAdory>>> to Chief Operating Officer. Steve-O>>> brings extensive experience in public company leadership and strategic transactions, including his role as Chairman of GT Biopharma>>> during its acquisition by Johnson & Johnson>>>. John McAdory>>>, who previously served as VP of Clinical Operations at CG Oncology>>>, will now oversee Oncolytics Biotech>>>'s clinical operations, development activities, preclinical research, and business development initiatives. Jared Kelly>>>, CEO of Oncolytics Biotech>>>, emphasized that these appointments are crucial for advancing pelareorep, expanding the immunotherapy platform, and pursuing strategic partnerships.

Key Actions
90 Oncolytics Biotech appointed to board Steve-O
90 Oncolytics Biotech promoted to COO John McAdory
Entities Involved
stock
Oncolytics Biotech
Oncolytics Biotech announced the appointment of Steve-O>>> to its Board of Directors and the promotion of John McAdory>>> to Chief Operating Officer, strengthening its leadership team for strategic growth and operational execution.
Importance 100 Sentiment 50
per
Steve-O
Steve-O>>> was appointed to the Board of Directors of Oncolytics Biotech>>>, bringing significant public company leadership and transaction experience to the company.
Importance 80 Sentiment 30
per
John McAdory
John McAdory>>> was promoted to Chief Operating Officer of Oncolytics Biotech>>>, where he will oversee clinical operations, development activities, and strategic partnerships.
Importance 80 Sentiment 30
per
Jared Kelly
Jared Kelly>>>, CEO of Oncolytics Biotech>>>, expressed enthusiasm for the new appointments, highlighting their expected contributions to the company's growth.
Importance 20 Sentiment 0
stock
GT Biopharma
GT Biopharma>>> is mentioned as a past company where Steve-O>>> served as Chairman during its acquisition by Johnson & Johnson>>>.
Importance 10 Sentiment 0
stock
Johnson & Johnson
Johnson & Johnson>>> acquired GT Biopharma>>>, a transaction referenced to highlight Steve-O>>>'s experience.
Importance 10 Sentiment 0
oth
CG Oncology
CG Oncology>>> is the previous employer of John McAdory>>> before he joined Oncolytics Biotech>>>.
Importance 10 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.